secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2024-12-05T23:59:59+00:00
Accession:  0001437749-24-036730
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart completes sentinel cohort enrollment in Phase 2b oral COVID vaccine trial
--------------------------------------------------------------------------------

- Sentinel cohort of 400 participants randomized 1:1 to Vaxart's oral pill vaccine or approved mRNA comparator.
- Last dose administered Nov 26, 2024; DSMB and FDA will review 30-day safety data before expanding.
- Upon favorable review and BARDA approval, second part will enroll approximately 10,000 participants.
- Project NextGen award (BARDA) valued at up to $456 million; trial includes >=25% over age 65.
- Primary endpoint is relative efficacy vs mRNA comparator for prevention of symptomatic COVID-19 disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774924036730/0001437749-24-036730-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774924036730/vxrt20241204_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-036730

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer